- Previous Close
0.7695 - Open
0.7910 - Bid 0.7525 x 200
- Ask 0.7611 x 400
- Day's Range
0.7510 - 0.7987 - 52 Week Range
0.5300 - 1.5400 - Volume
544,238 - Avg. Volume
1,483,504 - Market Cap (intraday)
134.008M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5200 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 9, 2012
- 1y Target Est
5.00
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
vaxart.comRecent News: VXRT
Performance Overview: VXRT
Trailing total returns as of 6/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VXRT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VXRT
Valuation Measures
Market Cap
141.28M
Enterprise Value
124.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.19
Price/Book (mrq)
2.54
Enterprise Value/Revenue
13.37
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.82%
Return on Equity (ttm)
-112.40%
Revenue (ttm)
8.88M
Net Income Avi to Common (ttm)
-81.74M
Diluted EPS (ttm)
-0.5200
Balance Sheet and Cash Flow
Total Cash (mrq)
36.66M
Total Debt/Equity (mrq)
42.58%
Levered Free Cash Flow (ttm)
-34.38M